Share Price and Basic Stock Data
Last Updated: October 8, 2025, 11:57 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Caprolactam Chemicals Ltd currently trades at ₹43.9 with a market capitalization of ₹20.2 Cr. The company’s Price-to-Earnings (P/E) ratio is not provided, but its Return on Equity (ROE) stands at 13.7%, while Return on Capital Employed (ROCE) is at 0.48%. The Operating Profit Margin (OPM) is reported at 14.29%, with a Net Profit margin of -0.71%. The company’s Promoter holding is at 54.04%, with a significant portion of shares held by the public at 45.95%. Caprolactam Chemicals Ltd’s Price-to-Book Value (P/BV) ratio is relatively high at 4.21x, indicating a premium valuation compared to sector peers.
A key strength of Caprolactam Chemicals Ltd lies in its healthy ROE, which suggests efficient utilization of shareholder funds. However, the negative Net Profit raises concerns about the company’s profitability and operational efficiency. The high P/BV ratio may also deter value-conscious investors. Risks include the company’s high borrowing levels at ₹8.72 Cr, which could impact its financial stability, especially given the Current Ratio (CCC) of 144.54 days and Interest Coverage Ratio (ICR) of 2.44x. Looking ahead, improving operational efficiency and reducing borrowing costs could enhance the company’s financial health and attractiveness to investors.
In conclusion, while Caprolactam Chemicals Ltd demonstrates strengths in ROE and promoter holding, investors should carefully assess the risks associated with negative net profits and high leverage. Monitoring the company’s efforts to enhance profitability and financial stability will be crucial for a more holistic investment decision.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Caprolactam Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 20.9 Cr. | 45.5 | 65.0/37.5 | 10.5 | 0.00 % | 0.48 % | 13.7 % | 10.0 | |
| Standard Industries Ltd | 121 Cr. | 18.7 | 31.1/17.5 | 18.6 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 4,163 Cr. | 567 | 900/484 | 772 | 2.79 % | 0.34 % | 1.13 % | 10.0 | |
| GHCL Ltd | 6,071 Cr. | 632 | 779/511 | 9.83 | 364 | 1.90 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 23,025 Cr. | 903 | 1,247/756 | 54.6 | 847 | 1.22 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,850.60 Cr | 462.20 | 39.34 | 382.68 | 1.02% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.63 | 2.75 | 2.51 | 2.37 | 2.22 | 2.06 | 1.97 | 1.49 | 1.44 | 1.12 | 1.71 | 2.29 | 1.61 |
| Expenses | 0.55 | 1.15 | 1.24 | 1.28 | 1.51 | 1.30 | 1.52 | 1.20 | 0.77 | 0.87 | 1.14 | 1.82 | 1.38 |
| Operating Profit | 0.08 | 1.60 | 1.27 | 1.09 | 0.71 | 0.76 | 0.45 | 0.29 | 0.67 | 0.25 | 0.57 | 0.47 | 0.23 |
| OPM % | 12.70% | 58.18% | 50.60% | 45.99% | 31.98% | 36.89% | 22.84% | 19.46% | 46.53% | 22.32% | 33.33% | 20.52% | 14.29% |
| Other Income | 0.16 | 0.01 | 0.01 | 0.00 | -0.01 | 0.15 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest | 0.06 | 0.13 | 0.14 | 0.14 | 0.15 | 0.14 | 0.13 | 0.11 | 0.12 | 0.14 | 0.14 | 0.17 | 0.18 |
| Depreciation | 0.31 | 0.22 | 0.22 | 0.33 | 0.39 | 0.37 | 0.39 | 0.40 | 0.42 | 0.38 | 0.40 | 0.40 | 0.41 |
| Profit before tax | -0.13 | 1.26 | 0.92 | 0.62 | 0.16 | 0.40 | -0.07 | -0.22 | 0.16 | -0.27 | 0.03 | -0.09 | -0.36 |
| Tax % | -107.69% | 24.60% | 25.00% | -17.74% | 0.00% | 25.00% | -28.57% | -31.82% | 31.25% | 0.00% | 0.00% | -66.67% | 25.00% |
| Net Profit | 0.02 | 0.95 | 0.69 | 0.74 | 0.17 | 0.30 | -0.06 | -0.16 | 0.12 | -0.27 | 0.04 | -0.03 | -0.45 |
| EPS in Rs | 0.04 | 2.07 | 1.50 | 1.61 | 0.37 | 0.65 | -0.13 | -0.35 | 0.26 | -0.59 | 0.09 | -0.07 | -0.98 |
Last Updated: May 31, 2025, 6:36 am
Below is a detailed analysis of the quarterly data for Caprolactam Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 1.61 Cr.. The value appears to be declining and may need further review. It has decreased from 2.29 Cr. (Dec 2024) to 1.61 Cr., marking a decrease of 0.68 Cr..
- For Expenses, as of Mar 2025, the value is 1.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.82 Cr. (Dec 2024) to 1.38 Cr., marking a decrease of 0.44 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.47 Cr. (Dec 2024) to 0.23 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Mar 2025, the value is 14.29%. The value appears to be declining and may need further review. It has decreased from 20.52% (Dec 2024) to 14.29%, marking a decrease of 6.23%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Dec 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Dec 2024) to 0.18 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Mar 2025, the value is 0.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.40 Cr. (Dec 2024) to 0.41 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.36 Cr.. The value appears to be declining and may need further review. It has decreased from -0.09 Cr. (Dec 2024) to -0.36 Cr., marking a decrease of 0.27 Cr..
- For Tax %, as of Mar 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from -66.67% (Dec 2024) to 25.00%, marking an increase of 91.67%.
- For Net Profit, as of Mar 2025, the value is -0.45 Cr.. The value appears to be declining and may need further review. It has decreased from -0.03 Cr. (Dec 2024) to -0.45 Cr., marking a decrease of 0.42 Cr..
- For EPS in Rs, as of Mar 2025, the value is -0.98. The value appears to be declining and may need further review. It has decreased from -0.07 (Dec 2024) to -0.98, marking a decrease of 0.91.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 2:22 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.92 | 2.85 | 4.88 | 3.23 | 4.07 | 5.19 | 6.51 | 6.31 | 2.07 | 9.84 | 6.96 | 6.74 |
| Expenses | 4.03 | 2.46 | 4.05 | 2.76 | 3.18 | 3.31 | 3.99 | 4.14 | 2.64 | 5.17 | 4.79 | 5.22 |
| Operating Profit | -0.11 | 0.39 | 0.83 | 0.47 | 0.89 | 1.88 | 2.52 | 2.17 | -0.57 | 4.67 | 2.17 | 1.52 |
| OPM % | -2.81% | 13.68% | 17.01% | 14.55% | 21.87% | 36.22% | 38.71% | 34.39% | -27.54% | 47.46% | 31.18% | 22.55% |
| Other Income | 0.01 | -0.15 | 0.40 | 0.01 | 0.07 | 0.07 | 0.06 | 0.09 | 0.41 | 0.02 | 0.18 | 0.01 |
| Interest | 0.00 | 0.06 | 0.11 | 0.12 | 0.19 | 0.34 | 0.30 | 0.30 | 0.28 | 0.57 | 0.50 | 0.63 |
| Depreciation | 0.19 | 0.23 | 0.51 | 0.47 | 0.57 | 0.97 | 1.02 | 1.07 | 1.03 | 1.15 | 1.58 | 1.59 |
| Profit before tax | -0.29 | -0.05 | 0.61 | -0.11 | 0.20 | 0.64 | 1.26 | 0.89 | -1.47 | 2.97 | 0.27 | -0.69 |
| Tax % | -6.90% | 0.00% | 14.75% | 0.00% | 15.00% | 23.44% | 24.60% | 26.97% | -12.93% | 14.14% | 29.63% | 4.35% |
| Net Profit | -0.27 | -0.06 | 0.52 | -0.12 | 0.17 | 0.50 | 0.95 | 0.65 | -1.28 | 2.55 | 0.20 | -0.71 |
| EPS in Rs | -0.59 | -0.13 | 1.13 | -0.26 | 0.37 | 1.09 | 2.07 | 1.41 | -2.78 | 5.54 | 0.43 | -1.54 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 77.78% | 966.67% | -123.08% | 241.67% | 194.12% | 90.00% | -31.58% | -296.92% | 299.22% | -92.16% | -455.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 888.89% | -1089.74% | 364.74% | -47.55% | -104.12% | -121.58% | -265.34% | 596.14% | -391.38% | -362.84% |
Caprolactam Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 1% |
| 3 Years: | 48% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | 78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 23% |
| 3 Years: | -9% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: September 10, 2025, 3:18 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 |
| Reserves | -3.08 | -3.13 | -2.61 | -2.73 | -2.56 | -2.06 | -1.10 | -0.52 | -1.80 | 0.74 | 0.95 | 0.23 |
| Borrowings | 0.09 | 0.82 | 0.95 | 1.37 | 1.89 | 3.58 | 2.45 | 2.15 | 3.76 | 5.69 | 5.86 | 8.72 |
| Other Liabilities | 0.52 | 1.15 | 0.98 | 1.10 | 2.35 | 1.29 | 1.16 | 0.97 | 3.77 | 0.49 | 0.25 | 0.74 |
| Total Liabilities | 2.12 | 3.43 | 3.91 | 4.33 | 6.27 | 7.41 | 7.11 | 7.20 | 10.33 | 11.52 | 11.66 | 14.29 |
| Fixed Assets | 1.19 | 2.92 | 2.96 | 3.38 | 3.56 | 6.37 | 6.07 | 5.50 | 5.26 | 10.22 | 10.29 | 10.31 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.96 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.93 | 0.51 | 0.95 | 0.95 | 2.71 | 1.04 | 1.04 | 1.70 | 1.11 | 1.30 | 1.37 | 3.98 |
| Total Assets | 2.12 | 3.43 | 3.91 | 4.33 | 6.27 | 7.41 | 7.11 | 7.20 | 10.33 | 11.52 | 11.66 | 14.29 |
Below is a detailed analysis of the balance sheet data for Caprolactam Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 4.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.60 Cr..
- For Reserves, as of Mar 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.95 Cr. (Mar 2024) to 0.23 Cr., marking a decrease of 0.72 Cr..
- For Borrowings, as of Mar 2025, the value is 8.72 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 5.86 Cr. (Mar 2024) to 8.72 Cr., marking an increase of 2.86 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.25 Cr. (Mar 2024) to 0.74 Cr., marking an increase of 0.49 Cr..
- For Total Liabilities, as of Mar 2025, the value is 14.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.66 Cr. (Mar 2024) to 14.29 Cr., marking an increase of 2.63 Cr..
- For Fixed Assets, as of Mar 2025, the value is 10.31 Cr.. The value appears strong and on an upward trend. It has increased from 10.29 Cr. (Mar 2024) to 10.31 Cr., marking an increase of 0.02 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 3.98 Cr.. The value appears strong and on an upward trend. It has increased from 1.37 Cr. (Mar 2024) to 3.98 Cr., marking an increase of 2.61 Cr..
- For Total Assets, as of Mar 2025, the value is 14.29 Cr.. The value appears strong and on an upward trend. It has increased from 11.66 Cr. (Mar 2024) to 14.29 Cr., marking an increase of 2.63 Cr..
However, the Borrowings (8.72 Cr.) are higher than the Reserves (0.23 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.20 | -0.43 | -0.12 | -0.90 | -1.00 | -1.70 | 0.07 | 0.02 | -4.33 | -1.02 | -3.69 | -7.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 25.14 | 1.28 | 38.89 | 40.68 | 69.05 | 2.81 | 16.82 | 27.19 | 5.29 | 25.22 | 33.56 | 152.72 |
| Inventory Days | 104.29 | 304.17 | 88.78 | 82.64 | 53.85 | 52.14 | 111.68 | |||||
| Days Payable | 43.45 | 861.81 | 799.05 | 344.34 | 173.52 | 111.73 | 119.85 | |||||
| Cash Conversion Cycle | 85.97 | 1.28 | 38.89 | 40.68 | -488.58 | -707.46 | 16.82 | 27.19 | -256.41 | -94.45 | -26.03 | 144.54 |
| Working Capital Days | 20.48 | -189.54 | -71.80 | -169.50 | -232.27 | -274.28 | -158.11 | -106.43 | -689.44 | -94.22 | -267.46 | -314.64 |
| ROCE % | -17.06% | 11.34% | 27.64% | 0.32% | 10.91% | 19.52% | 25.85% | 19.54% | -18.61% | 40.25% | 6.86% | -0.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
| Diluted EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
| Cash EPS (Rs.) | 1.91 | 3.87 | 8.05 | -0.53 | 3.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
| Revenue From Operations / Share (Rs.) | 14.65 | 15.12 | 21.39 | 4.50 | 13.72 |
| PBDIT / Share (Rs.) | 3.33 | 5.11 | 10.20 | -0.35 | 4.90 |
| PBIT / Share (Rs.) | -0.11 | 1.67 | 7.69 | -2.60 | 2.58 |
| PBT / Share (Rs.) | -1.49 | 0.59 | 6.46 | -3.20 | 1.94 |
| Net Profit / Share (Rs.) | -1.54 | 0.42 | 5.54 | -2.79 | 1.41 |
| PBDIT Margin (%) | 22.75 | 33.81 | 47.66 | -7.87 | 35.72 |
| PBIT Margin (%) | -0.81 | 11.07 | 35.95 | -57.88 | 18.83 |
| PBT Margin (%) | -10.14 | 3.91 | 30.18 | -71.24 | 14.12 |
| Net Profit Margin (%) | -10.51 | 2.83 | 25.89 | -61.97 | 10.31 |
| Return on Networth / Equity (%) | -14.67 | 3.55 | 47.70 | -45.82 | 15.94 |
| Return on Capital Employeed (%) | -1.12 | 10.62 | 44.09 | -21.52 | 29.13 |
| Return On Assets (%) | -4.96 | 1.69 | 22.12 | -12.40 | 9.30 |
| Long Term Debt / Equity (X) | 0.00 | 0.29 | 0.49 | 0.98 | 0.00 |
| Total Debt / Equity (X) | 1.80 | 1.06 | 1.06 | 1.34 | 0.52 |
| Asset Turnover Ratio (%) | 0.51 | 0.60 | 0.90 | 0.23 | 0.90 |
| Current Ratio (X) | 0.38 | 0.24 | 0.34 | 0.21 | 0.53 |
| Quick Ratio (X) | 0.34 | 0.22 | 0.31 | 0.18 | 0.50 |
| Inventory Turnover Ratio (X) | 2.25 | 6.31 | 5.53 | 4.83 | 0.13 |
| Interest Coverage Ratio (X) | 2.44 | 4.73 | 8.26 | -0.58 | 7.58 |
| Interest Coverage Ratio (Post Tax) (X) | -0.12 | 1.40 | 5.49 | -3.64 | 3.19 |
| Enterprise Value (Cr.) | 28.94 | 29.47 | 29.54 | 25.41 | 16.72 |
| EV / Net Operating Revenue (X) | 4.29 | 4.24 | 3.00 | 12.28 | 2.65 |
| EV / EBITDA (X) | 18.88 | 12.53 | 6.30 | -156.02 | 7.42 |
| MarketCap / Net Operating Revenue (X) | 3.01 | 3.40 | 2.45 | 10.54 | 2.39 |
| Price / BV (X) | 4.21 | 4.27 | 4.51 | 7.79 | 3.70 |
| Price / Net Operating Revenue (X) | 3.01 | 3.41 | 2.45 | 10.54 | 2.39 |
| EarningsYield | -0.03 | 0.01 | 0.10 | -0.05 | 0.04 |
After reviewing the key financial ratios for Caprolactam Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 3. It has decreased from 3.87 (Mar 24) to 1.91, marking a decrease of 1.96.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.65. It has decreased from 15.12 (Mar 24) to 14.65, marking a decrease of 0.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.33. This value is within the healthy range. It has decreased from 5.11 (Mar 24) to 3.33, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.11. This value is below the healthy minimum of 0. It has decreased from 1.67 (Mar 24) to -0.11, marking a decrease of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 0. It has decreased from 0.59 (Mar 24) to -1.49, marking a decrease of 2.08.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 2. It has decreased from 0.42 (Mar 24) to -1.54, marking a decrease of 1.96.
- For PBDIT Margin (%), as of Mar 25, the value is 22.75. This value is within the healthy range. It has decreased from 33.81 (Mar 24) to 22.75, marking a decrease of 11.06.
- For PBIT Margin (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 10. It has decreased from 11.07 (Mar 24) to -0.81, marking a decrease of 11.88.
- For PBT Margin (%), as of Mar 25, the value is -10.14. This value is below the healthy minimum of 10. It has decreased from 3.91 (Mar 24) to -10.14, marking a decrease of 14.05.
- For Net Profit Margin (%), as of Mar 25, the value is -10.51. This value is below the healthy minimum of 5. It has decreased from 2.83 (Mar 24) to -10.51, marking a decrease of 13.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is -14.67. This value is below the healthy minimum of 15. It has decreased from 3.55 (Mar 24) to -14.67, marking a decrease of 18.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.12. This value is below the healthy minimum of 10. It has decreased from 10.62 (Mar 24) to -1.12, marking a decrease of 11.74.
- For Return On Assets (%), as of Mar 25, the value is -4.96. This value is below the healthy minimum of 5. It has decreased from 1.69 (Mar 24) to -4.96, marking a decrease of 6.65.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.29 (Mar 24) to 0.00, marking a decrease of 0.29.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.80. This value exceeds the healthy maximum of 1. It has increased from 1.06 (Mar 24) to 1.80, marking an increase of 0.74.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has decreased from 0.60 (Mar 24) to 0.51, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 1.5. It has increased from 0.24 (Mar 24) to 0.38, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.34, marking an increase of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.25. This value is below the healthy minimum of 4. It has decreased from 6.31 (Mar 24) to 2.25, marking a decrease of 4.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 3. It has decreased from 4.73 (Mar 24) to 2.44, marking a decrease of 2.29.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.12. This value is below the healthy minimum of 3. It has decreased from 1.40 (Mar 24) to -0.12, marking a decrease of 1.52.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28.94. It has decreased from 29.47 (Mar 24) to 28.94, marking a decrease of 0.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.29. This value exceeds the healthy maximum of 3. It has increased from 4.24 (Mar 24) to 4.29, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 18.88. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 18.88, marking an increase of 6.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.40 (Mar 24) to 3.01, marking a decrease of 0.39.
- For Price / BV (X), as of Mar 25, the value is 4.21. This value exceeds the healthy maximum of 3. It has decreased from 4.27 (Mar 24) to 4.21, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.41 (Mar 24) to 3.01, marking a decrease of 0.40.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.03, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caprolactam Chemicals Ltd:
- Net Profit Margin: -10.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.12% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -14.67% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.34
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 39.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.8
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.51%
About the Company - Qualitative Analysis
Caprolactam Chemicals Ltd. is a Public Limited Listed company incorporated on 18/11/1988 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24110MH1988PLC049683 and registration number is 049683. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 6.74 Cr. and Equity Capital is Rs. 4.60 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | B-31, MIDC, Mahad, Raigad District Maharashtra 402302 | caprolactam@gmail.com http://www.caprolactam.com |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Zaver Shankarlal Bhanushali | Chairperson & Managing Director |
| Mr. Siddharth Shankarlal Bhanushali | WholeTime Director & CFO |
| Mr. Viren Jaysukhlal Jasani | Ind. Non-Executive Director |
| Mr. Kamlesh Damji Joisher | Ind. Non-Executive Director |
| Mrs. Poonam Bhavin Bhanushali | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Caprolactam Chemicals Ltd?
Caprolactam Chemicals Ltd's intrinsic value (as of 10 October 2025) is 17.61 which is 61.30% lower the current market price of 45.50, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹20.9 Cr. market cap, FY2025-2026 high/low of 65.0/37.5, reserves of ₹0.23 Cr, and liabilities of 14.29 Cr.
What is the Market Cap of Caprolactam Chemicals Ltd?
The Market Cap of Caprolactam Chemicals Ltd is 20.9 Cr..
What is the current Stock Price of Caprolactam Chemicals Ltd as on 10 October 2025?
The current stock price of Caprolactam Chemicals Ltd as on 10 October 2025 is 45.5.
What is the High / Low of Caprolactam Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Caprolactam Chemicals Ltd stocks is 65.0/37.5.
What is the Stock P/E of Caprolactam Chemicals Ltd?
The Stock P/E of Caprolactam Chemicals Ltd is .
What is the Book Value of Caprolactam Chemicals Ltd?
The Book Value of Caprolactam Chemicals Ltd is 10.5.
What is the Dividend Yield of Caprolactam Chemicals Ltd?
The Dividend Yield of Caprolactam Chemicals Ltd is 0.00 %.
What is the ROCE of Caprolactam Chemicals Ltd?
The ROCE of Caprolactam Chemicals Ltd is 0.48 %.
What is the ROE of Caprolactam Chemicals Ltd?
The ROE of Caprolactam Chemicals Ltd is 13.7 %.
What is the Face Value of Caprolactam Chemicals Ltd?
The Face Value of Caprolactam Chemicals Ltd is 10.0.